Contradicting standard advice given to most patients that the preferred medication is a less-expensive generic medication, rather than a brand-name drug, some health insurers are telling consumers the opposite: they must buy brand-name drugs even when cheaper generics are available.
Contradicting standard advice given to most patients that the preferred medication is a less-expensive generic medication, rather than a brand-name drug, some health insurers are telling consumers the opposite: they must buy brand-name drugs even when cheaper generics are available. Driven by better margins for pharmacy benefit managers (PBMs), the practice leaves patients paying higher out-of-pocket costs.
The practice, report The New York Times and ProPublica, is not limited to generics, but is also spreading to biosimilars. UnitedHealthcare recently informed healthcare providers that it prefers the reference biologic drug Remicade (infliximab) to the infliximab biosimilars that have recently become available at lower list prices.
The Times—ProPublica article states that a preference for more expensive branded drugs has appeared sporadically for years, but is increasing as pharmaceutical companies maximize efforts to extract the last profits from products that face cheaper generic competition. “Companies are cutting deals that give consumers little choice but to buy brand-name drugs,” the report notes, and sometimes patients end up paying more than they would for generics. In recent months, some insurers and PBMs have insisted that patients forgo generics and buy brand-name drugs including Adderall XR, a treatment for attention-deficit/hyperactivity disorder (ADHD); Zetia, a cholesterol treatment; Aggrenox, a stroke-prevention drug; and Voltaren, a pain-relieving gel.
Some health insurers require members to have prescriptions filled with brand-name drugs and do not charge them more than they would for generics. However, for the 29% of Americans with employer-provided health insurance who have high-deductible insurance plans, picking up the cost difference between branded and generic drugs is a heavy burden, as they have to pay the full sticker price of medications before they meet their deductibles.
A spokesman for UnitedHealthcare acknowledged that the insurer at times prefers brand-name drugs, but said that by “providing access to these drugs at lower cost, the company is able to improve affordability for customers and members.” Many patients, however, are unaware that pharmacies and physicians can seek an exemption from the insurer if they want the generic instead, according to The Times—ProPublica article.
Shire, for example, has negotiated discounts with PBMs and insurers to preserve much of its market share—29% last year. (Most brand-name products’ market share falls to less than 6% in the 2 years after the introduction of the first generic competitor.) Shire and other brand-name drug makers are no longer content to allow sales of their products to plummet when generic competitors appear in the marketplace, the report states, and negotiate arrangements so PBMs and insurers afford a preferred-drug status to their products.
A Shire spokesperson was quoted in The Times—ProPublica report as saying that the company was able to hold onto market share for Adderall XR by offering insurers and government programs prices that are competitive with those of generics. Shire has given increasing discounts to PBMs and insurers for preferential treatment of their products, a deal that did not mean lowering the drug’s list price but rather negotiating rebates that were paid to insurers and PBMs rather than to patients.
In December, CVS Caremark informed pharmacies that some of its Medicare prescription drug plans would cover only branded versions of 12 drugs. Some of those drugs have had generic competitors for over a year. Among the products affected by this change were the antipsychotic drug Invega, as well as the multiple sclerosis treatment Copaxone. Because Medicare cannot, by law, negotiate directly with drug manufacturers, the public pays the bill when Medicare enrollees’ drugs cost more.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.